Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant

被引:234
作者
Muller, RH [1 ]
Ruhl, D [1 ]
Runge, S [1 ]
SchulzeForster, K [1 ]
Mehnert, W [1 ]
机构
[1] FREE UNIV BERLIN,DEPT BIOCHEM PHARMACOL,D-12169 BERLIN,GERMANY
关键词
solid lipid nanoparticles; cytotoxicity; HL60; cells; poloxamer; Tween; 80; sodium dodecyl sulphate;
D O I
10.1023/A:1012043315093
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Assessment of the in vitro cytotoxicity of solid lipid nanoparticles (SLNs) as a function of lipid matrix (Dynasan 114, Compritol ATO 888), and stabilizing surfactant (poloxamers, Tween 80, soya lecithin, and sodium dodecyl sulphate). Comparison with other colloidal carriers should determine their potential use in the clinic. Methods, SLNs were produced by high pressure homogenisation. Cytotoxicity was assessed by measuring the viability of HL60 cells and human granulocytes after incubation with SLNs. Particle internalisation was quantified by chemiluminescence measurements. Results. The nature of the lipid had no effect on viability; distinct differences were found for the surfactants. Binding to the SLN surface reduced markedly the cytotoxic effect of the surfactants, e.g., up to a factor of 65 for poloxamer 184. The permanent HL60 cell line-differentiated from cells with granulocyte characteristics by retinoic acid treatment-yielded results identical to freshly isolated human granulocytes. In general, the SLNs showed a lower cytotoxicity compared to polyalkylcyanoacrylate and polylactic/glycolic acid (PLA/GA) nanoparticles. Conclusions. Because the results are identical when using human granulocytes, differentiated HL60 cells can be used as an easily accessible in vitro test system for i.v. injectable SLN formulations. The SLNs appear suitable as a drug carrier system for potential intravenous use due to their very low cytotoxicity in vitro.
引用
收藏
页码:458 / 462
页数:5
相关论文
共 20 条
  • [1] BRASSEUR F, 1983, P 3 INT C PHARM TECH, V2, P194
  • [2] BRAUER A, 1991, THESIS U KIEL
  • [3] BRAUER A, 1989, ARCH PHARM, V322, P755
  • [4] BRAUER A, 1990, ACTA PHARM TECHNOL, V36, pS33
  • [5] INDUCTION OF DIFFERENTIATION OF THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE (HL-60) BY RETINOIC ACID
    BREITMAN, TR
    SELONICK, SE
    COLLINS, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (05): : 2936 - 2940
  • [6] COUVREUR P, 1988, CRIT REV THER DRUG, V5, P1
  • [7] Gasco M.R., 1991, Patent No. [EP0526666B1, 0526666]
  • [8] THE EFFECTS OF POLYALKYLCYANOACRYLATE NANOPARTICLES ON HUMAN NORMAL AND MALIGNANT MESENCHYMAL CELLS-INVITRO
    GIPPS, EM
    GROSCURTH, P
    KREUTER, J
    SPEISER, PP
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 40 (1-2) : 23 - 31
  • [9] PHASE-I CLINICAL-TRIAL AND PHARMACOKINETIC EVALUATION OF DOXORUBICIN CARRIED BY POLYISOHEXYLCYANOACRYLATE NANOPARTICLES
    KATTAN, J
    DROZ, JP
    COUVREUR, P
    MARINO, JP
    BOUTANLAROZE, A
    ROUGIER, P
    BRAULT, P
    VRANCKX, H
    GROGNET, JM
    MORGE, X
    SANCHOGARNIER, H
    [J]. INVESTIGATIONAL NEW DRUGS, 1992, 10 (03) : 191 - 199
  • [10] KOOSHA F, 1989, J CONTROL RELEASE, V9, P145